Key facts
- This page summarizes David Jin Yoo's Form 4 filing for Bellevue Life Sciences Acquisition Corp. (OSRH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Mar 2023, 16:06.
David Jin Yoo - 23 Mar 2023 Form 4 Insider Report for Bellevue Life Sciences Acquisition Corp. (OSRH)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- OSRH
- Reported as of
- 23 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2023, 16:06:19 UTC
- Prior SEC filing
- 09 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Jin Yoo
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Jin Yoo filed Form 4 for Bellevue Life Sciences Acquisition Corp. (OSRH) on 27 Mar 2023.
Change
- Previous filing in this sequence was filed on 09 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLAC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 23 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLAC
transaction
Derivative
Warrant for Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 23 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $11.50
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor"), to Mr. Yoo for his service as Chief Financial Officer.
Footnote F2
Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.